Study reveals how cells destroy faulty proteins in cystic fibrosisAugust 11, 2006CHAPEL HILL - The cellular system that degrades faulty proteins created by the cystic fibrosis gene has been identified by University of North Carolina at Chapel Hill scientists. Turning off the degradation system allows some proteins to regain their proper shape, offering a new avenue for treatments aimed at curing the disease. Cystic fibrosis (CF) is a fatal disease caused by a defective gene that produces a misshapen form of the protein cystic fibrosis transmembrane conductance regulator (CFTR). People with cystic fibrosis do not have enough CFTR for their cells to work normally because their bodies quickly destroy the mutant protein. "Most cases of CF are caused by the inability of faulty CFTR to get in the correct shape, which leads cells to place it in the trash bin," said senior author Dr. Douglas Cyr, professor of cell and developmental biology at UNC School of Medicine. "Our research helps define the basic mechanism for CF and identify targets for the development of therapeutics designed to get CFTR into shape and allow it function normally in the lung," Cyr said. The results, published Aug. 11, 2006, in the journal Cell, point to several possible targets for the development of new treatments aimed at stopping the disease, the researchers said. Scientists have known for some time that treatment of cultured cells with compounds known as chemical chaperones can increase the fitness of misshaped CFTR and get it into proper shape. Thus, "If we can figure out how to get CFTR into the right shape, we can cure the disease," Cyr said. To better understand how to fix CFTR, Cyr's research team at the UNC Cystic Fibrosis Pulmonary Research and Treatment Center focused on identifying the cellular system that disposes of faulty CFTR. The investigators identified cell components that specifically recognizes misshapen CFTR and drops it in the molecular trash bin. The team found that turning off these components - the cell's trash collectors - extends the life of faulty CFTR proteins and thereby enables some of it to assume a functional shape. The trash collectors newly identified by the Cyr group are two different ubiquitin ligases, proteins that specifically recognize misshaped regions of CFTR and tag them with a degradation signal known as ubiquitin. The ubiquitin tag tells the cell to destroy the marked CFTR, a process overseen by a destroyer called the proteasome. This trash system is known as the ubiquitin proteasome pathway. "We've identified the trash collectors that recognize misfolded proteins, decide if they might be toxic to the cell and mark them with ubiquitin. The ubiquitinated proteins, including faulty CFTR, are then degraded or shredded by the proteasome," Cyr said. "Understanding this pathway gives us greater insight into what's wrong with the protein - information that will help people design better therapeutics for the disease," Cyr said. University of North Carolina School of Medicine |
|||||||||||||||||||||
| Related Cystic Fibrosis Current Events and Cystic Fibrosis News Articles Causative gene of a rare disorder discovered by sequencing only protein-coding regions of genome For the first time, scientists have successfully used a method called exome sequencing to quickly discover a previously unknown gene responsible for a mendelian disorder. Bacteria 'launch a shield' to resist attack Researchers from the University of Copenhagen and the Technical University of Denmark along with other collaborators in Denmark and the US found that the bacterium Pseudomonas aeruginosa can 'switch on' production of molecules that kill white blood cells - preventing the bacteria being eliminated by the body's immune system. Protein critical for insulin secretion may be contributor to diabetes A cellular protein from a family involved in several human diseases is crucial for the proper production and release of insulin, new research has found, suggesting that the protein might play a role in diabetes. New clinical guidelines for exacerbations in cystic fibrosis The American Thoracic Society has released new clinical guidelines for the treatment of exacerbations in cystic fibrosis based on a review of the literature on current clinical practices. Nanoparticle treatment for burns curbs infection, reduces inflammation Treating second-degree burns with a nanoemulsion lotion sharply curbs bacterial growth and reduces inflammation that otherwise can jeopardize recovery, University of Michigan scientists have shown in initial laboratory studies. Research Matters at the Arizona Health Sciences Center (AHSC): UA Researchers Seek Safer Cystic Fibrosis Test Researchers from The University of Arizona Colleges of Pharmacy and Medicine are teaming up to try to invent a novel non-invasive lung test for cystic fibrosis sufferers. Species diversity helps ASU researchers refine analyses of human gene mutations In the new era of personalized medicine, physicians hope to provide earlier diagnoses and improve therapy by evaluating patients' genetic blueprints. But, as a new bioinformatics study emphasizes, the first step must be to correctly decipher the deluge of information locked in our DNA and determine its impact on human health. New developments in reproductive medicine Three out of ten women who undergo polar body diagnosis go on to have a child. Faster, cheaper way to find disease genes in human genome passes initial test University of Washington (UW) researchers have successfully developed a novel genome-analysis strategy for more rapid, lower cost discovery of possible gene-disease links. Mutation responsible for cystic fibrosis also involved in muscle atrophy Patients with cystic fibrosis (CF) usually experience significant muscle loss, a symptom traditionally considered to be a secondary complication of the devastating genetic disease. More Cystic Fibrosis Current Events and Cystic Fibrosis News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||